serrapeptase-pain

Relative to the comparator drugs (betamethasone and paracetamol), serrapeptase was less effective in reducing pain and inflammation associated with third molar surgery when taken at the standard 30mg dosage; relative to placebo, there was no significant difference.

In patients undergoing jaw surgery (removal of third molar), 30mg serrapeptase daily for up to a week was more effective than placebo in reducing pain and swelling although trismus (opening of the jaw) was unaffected.

10mg serrapeptase thrice daily (30mg total) for 3 days in women with breast engorgement was able to reduce pain and tenderness as assessed by self-report surveys.

In persons with superficial thrombophlebitis given 30mg serrapeptase (10mg thrice daily) relative to the comparator drug Protease S (Seaprose S; no placebo control in this study) noted that both drugs were able to reduce pain and symptoms of thrombophlebitis, but the symptoms alleviation seen with serrapeptase (65%) was outperformed by protease S (85%).

In persons with acute or chronic ear, nose or throat disorders given 10mg of serrapeptase thrice daily (30mg total), supplementation was more effective than placebo in reducing abnormalities of mucus production and swallowing and was also analgesic.